Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology

Something Old, Something New

Anagha Bangalore Kumar, Rachel Maus, Svetomir Nenad Markovic

Research output: Contribution to journalReview article

2 Citations (Scopus)

Abstract

The concept of exploiting the immune system to treat cancer forms the basis of immuno-oncology. Since its birth in the late 1800s, immuno-oncology, or cancer immunotherapy, has come a long way. With better understanding of the complex relationship between tumor and the immune system, we have been able to explore and develop various modalities of anticancer therapies. In this review, we summarize the main strategies of immunotherapy that are available today: monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy. We also highlight the unique set of adverse effects associated with modern immunotherapy and propose nonsteroidal immunomodulators and anticytokine antibodies as treatment options for toxicities. The future of immuno-oncology is discussed, including combination therapy, drug-antibody conjugates, epigenetic drugs, using nanoparticles for drug delivery, new antigen discovery, and developing biomarkers to assess treatment responses. A data search was conducted using PubMed and included studies published through November 1, 2017. Search terms used include cancer immunotherapy, pembrolizumab, ipilimumab, nivolumab, PD-1 inhibitors, PD-L1 inhibitors, checkpoint inhibitors, anticancer vaccines, TVEC, and adoptive cell therapy.

Original languageEnglish (US)
Pages (from-to)917-936
Number of pages20
JournalMayo Clinic Proceedings
Volume93
Issue number7
DOIs
StatePublished - Jul 1 2018

Fingerprint

Immunotherapy
Immunity
Cell- and Tissue-Based Therapy
Immune System Phenomena
Neoplasms
Vaccines
Antibodies
Immunologic Factors
Combination Drug Therapy
PubMed
Epigenomics
Pharmaceutical Preparations
Nanoparticles
Immune System
Therapeutics
Biomarkers
Monoclonal Antibodies
Parturition
Cytokines
T-Lymphocytes

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology : Something Old, Something New. / Bangalore Kumar, Anagha; Maus, Rachel; Markovic, Svetomir Nenad.

In: Mayo Clinic Proceedings, Vol. 93, No. 7, 01.07.2018, p. 917-936.

Research output: Contribution to journalReview article

@article{566d769fc5014cddace227bca8574a48,
title = "Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology: Something Old, Something New",
abstract = "The concept of exploiting the immune system to treat cancer forms the basis of immuno-oncology. Since its birth in the late 1800s, immuno-oncology, or cancer immunotherapy, has come a long way. With better understanding of the complex relationship between tumor and the immune system, we have been able to explore and develop various modalities of anticancer therapies. In this review, we summarize the main strategies of immunotherapy that are available today: monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy. We also highlight the unique set of adverse effects associated with modern immunotherapy and propose nonsteroidal immunomodulators and anticytokine antibodies as treatment options for toxicities. The future of immuno-oncology is discussed, including combination therapy, drug-antibody conjugates, epigenetic drugs, using nanoparticles for drug delivery, new antigen discovery, and developing biomarkers to assess treatment responses. A data search was conducted using PubMed and included studies published through November 1, 2017. Search terms used include cancer immunotherapy, pembrolizumab, ipilimumab, nivolumab, PD-1 inhibitors, PD-L1 inhibitors, checkpoint inhibitors, anticancer vaccines, TVEC, and adoptive cell therapy.",
author = "{Bangalore Kumar}, Anagha and Rachel Maus and Markovic, {Svetomir Nenad}",
year = "2018",
month = "7",
day = "1",
doi = "10.1016/j.mayocp.2018.03.028",
language = "English (US)",
volume = "93",
pages = "917--936",
journal = "Mayo Clinic Proceedings",
issn = "0025-6196",
publisher = "Elsevier Science",
number = "7",

}

TY - JOUR

T1 - Pharmacologic Modulation of Human Immunity in the Era of Immuno-oncology

T2 - Something Old, Something New

AU - Bangalore Kumar, Anagha

AU - Maus, Rachel

AU - Markovic, Svetomir Nenad

PY - 2018/7/1

Y1 - 2018/7/1

N2 - The concept of exploiting the immune system to treat cancer forms the basis of immuno-oncology. Since its birth in the late 1800s, immuno-oncology, or cancer immunotherapy, has come a long way. With better understanding of the complex relationship between tumor and the immune system, we have been able to explore and develop various modalities of anticancer therapies. In this review, we summarize the main strategies of immunotherapy that are available today: monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy. We also highlight the unique set of adverse effects associated with modern immunotherapy and propose nonsteroidal immunomodulators and anticytokine antibodies as treatment options for toxicities. The future of immuno-oncology is discussed, including combination therapy, drug-antibody conjugates, epigenetic drugs, using nanoparticles for drug delivery, new antigen discovery, and developing biomarkers to assess treatment responses. A data search was conducted using PubMed and included studies published through November 1, 2017. Search terms used include cancer immunotherapy, pembrolizumab, ipilimumab, nivolumab, PD-1 inhibitors, PD-L1 inhibitors, checkpoint inhibitors, anticancer vaccines, TVEC, and adoptive cell therapy.

AB - The concept of exploiting the immune system to treat cancer forms the basis of immuno-oncology. Since its birth in the late 1800s, immuno-oncology, or cancer immunotherapy, has come a long way. With better understanding of the complex relationship between tumor and the immune system, we have been able to explore and develop various modalities of anticancer therapies. In this review, we summarize the main strategies of immunotherapy that are available today: monoclonal antibodies, anticancer vaccines, cytokines, and adoptive T-cell therapy. We also highlight the unique set of adverse effects associated with modern immunotherapy and propose nonsteroidal immunomodulators and anticytokine antibodies as treatment options for toxicities. The future of immuno-oncology is discussed, including combination therapy, drug-antibody conjugates, epigenetic drugs, using nanoparticles for drug delivery, new antigen discovery, and developing biomarkers to assess treatment responses. A data search was conducted using PubMed and included studies published through November 1, 2017. Search terms used include cancer immunotherapy, pembrolizumab, ipilimumab, nivolumab, PD-1 inhibitors, PD-L1 inhibitors, checkpoint inhibitors, anticancer vaccines, TVEC, and adoptive cell therapy.

UR - http://www.scopus.com/inward/record.url?scp=85048457705&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048457705&partnerID=8YFLogxK

U2 - 10.1016/j.mayocp.2018.03.028

DO - 10.1016/j.mayocp.2018.03.028

M3 - Review article

VL - 93

SP - 917

EP - 936

JO - Mayo Clinic Proceedings

JF - Mayo Clinic Proceedings

SN - 0025-6196

IS - 7

ER -